TransMedics Group, Inc. (TMDX) Balance Sheet
As of 2026-06-30 (10-Q), TransMedics Group, Inc. (TMDX) reported total assets of $1.5B, total liabilities of $946.3M and shareholders' equity of $518.1M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $491.1M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
TMDXTransMedics Group, Inc.Follow TMDX — free
—
Price chart with a free account
- Market cap
- 2.5B
- P/E TTM
- —
- Dividend yield
- 0.0%
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
| Line | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 0.02 | 0.03 | 0.03 | 0.20 | 0.40 | 0.34 | 0.49 | 0.49 | |
| Short-term investments | 0.06 | 0.10 | 0.07 | — | — | — | — | — | |
| Receivables | 0.01 | 0.01 | 0.01 | 0.03 | 0.06 | 0.10 | 0.08 | 0.10 | |
| Inventory | 0.01 | 0.01 | 0.01 | 0.02 | 0.04 | 0.05 | 0.05 | 0.05 | |
| Current assets | 0.10 | 0.15 | 0.12 | 0.25 | 0.51 | 0.50 | 0.64 | 0.65 | |
| Total assets | 0.11 | 0.15 | 0.13 | 0.28 | 0.71 | 0.80 | 1.07 | 1.46 | |
| Current liabilities | 0.02 | 0.01 | 0.02 | 0.02 | 0.05 | 0.06 | 0.09 | 0.10 | |
| Long-term debt | 0.03 | 0.03 | 0.04 | 0.06 | — | — | — | — | |
| Short-term debt | — | — | — | — | — | — | 0.01 | 0.02 | |
| Total liabilities | 0.05 | 0.05 | 0.07 | 0.09 | 0.57 | 0.58 | 0.60 | 0.95 | |
| Shareholders' equity | 0.05 | 0.10 | 0.07 | 0.19 | 0.14 | 0.23 | 0.47 | 0.52 |
USD billions · SEC XBRL
TransMedics Group, Inc. — questions
- How much cash does TransMedics Group, Inc. have?
- $491.1M in cash and cash equivalents as of 2026-06-30.
- How much debt does TransMedics Group, Inc. have?
- $20.0M due within a year as of 2026-06-30.
- What are TransMedics Group, Inc.'s total assets?
- $1.5B as of 2026-06-30.
- What is TransMedics Group, Inc.'s shareholders' equity?
- $518.1M as of 2026-06-30.
Every figure on this page comes from TransMedics Group, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.